1 |
Franco Machado J, Silva RD, Melo R, G Correia JD. Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics. Molecules 2018;24:E49. [PMID: 30583594 DOI: 10.3390/molecules24010049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
2 |
Łażewska D, Kieć-Kononowicz K. Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017). Expert Opin Ther Pat 2018;28:175-96. [PMID: 29334795 DOI: 10.1080/13543776.2018.1424135] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
|
3 |
Mori W, Takei M, Furutsuka K, Fujinaga M, Kumata K, Muto M, Ohkubo T, Hashimoto H, Tamagnan G, Higuchi M, Kawamura K, Zhang MR. Comparison between [18F]fluorination and [18F]fluoroethylation reactions for the synthesis of the PDE10A PET radiotracer [18F]MNI-659. Nucl Med Biol 2017;55:12-8. [PMID: 28972915 DOI: 10.1016/j.nucmedbio.2017.08.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
4 |
Kimura Y, Takahata K, Shimazaki T, Kitamura S, Seki C, Ikoma Y, Ichise M, Kawamura K, Yamada M, Zhang MR, Higuchi M, Nishino I, Suhara T. Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand, [11C]TASP457. Eur J Nucl Med Mol Imaging 2021. [PMID: 34651222 DOI: 10.1007/s00259-021-05571-1] [Reference Citation Analysis]
|